Downregulation of miR-503 in Activated Kidney Fibroblasts Disinhibits KCNN4 in an in Vitro Model of Kidney Fibrosis

Autor: Christoph Mann, Brajesh Pratap Kaistha, Michael Kacik, Thorsten Stiewe, Joachim Hoyer

Publikováno v: Kidney & Blood Pressure Research, Vol 44, Iss 1, Pp 113-122 (2019)

Background/Aims: Activated fibroblasts are key controllers of extracellular matrix turnover in kidney fibrosis, the pathophysiological end stage of chronic kidney disease. The proliferation of activated fibroblasts depends on the expression of the ca

Externí odkaz: https://doaj.org/article/6672c02e6b8c446dbeeac6356f06f128

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Autor: Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske

Publikováno v: The Lancet Haematology. 9:e810-e821

Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa4e06ca167ce956ab3c750cb5371c4d
https://doi.org/10.1016/s2352-3026(22)00263-0

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells

Autor: Elisabeth K. M. Mack, Sören Hartmann, Petra Ross, Ellen Wollmer, Christoph Mann, Andreas Neubauer, Cornelia Brendel, Jörg Hoffmann

Publikováno v: Annals of Hematology. 101:811-824

With the advent of novel, highly effective therapies for multiple myeloma (MM), classical serologic monitoring appears insufficient for response assessment and prediction of relapse. Moreover, serologic studies in MM are hampered by interference of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc688bde5e653920c723983063a0f3a5
https://doi.org/10.1007/s00277-022-04771-5

Bone Marrow and Peripheral Blood Aberrant Plasma Cell Assessment by Next-Generation Flow Cytometry in MM Patients

Autor: Katharina, Kriegsmann, Calin, Manta, Ricarda, Schwab, Elias K, Mai, Marc S, Raab, Hans J, Salwender, Roland, Fenk, Britta, Besemer, Jan, Dürig, Roland, Schroers, Ivana, von Metzler, Mathias, Hänel, Christoph, Mann, Anne M, Asemissen, Bernhard, Heilmeier, Uta, Bertsch, Stefanie, Huhn, Carsten, Müller-Tidow, Hartmut, Goldschmidt, Michael, Hundemer

Publikováno v: Blood advances.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::994b1247a0b6418777ccce273942eb8b
https://pubmed.ncbi.nlm.nih.gov/35914229

Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

Autor: Lisa B. Leypoldt, Anne Marie Asemissen, Britta Besemer, Mathias Haenel, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Hans Christian Reinhardt, Peter Staib, Christoph Mann, Raphael Lutz, Markus Munder, Ullrich Graeven, Rudolf Peceny, Hans Salwender, Anna Jauch, Manola Zago, Axel Benner, Diana Tichy, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C. Weisel, German Speaking Myeloma Multicenter Group (GMMG)

Publikováno v: SSRN Electronic Journal.

Background: High-risk (HR) multiple myeloma (MM) has an impaired prognostic outcome. Addition of anti-CD38 monoclonal antibodies to standard-of-care regimens improved response rates and depth of response. Here, we report a prespecified interim analys

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b70798192651ed5a20c75c16776d716
https://doi.org/10.2139/ssrn.3790459